-
2025-524594-16-00
1
2026-05-12
Patients with prostate cancer with:
- suspected metastasis who are can
-
2023-509628-16-00
5
2026-05-07
Small Cell Lung Cancer (SCLC)
-
2025-523717-29-00
5
2026-04-28
HFpEF or HFmrEF and obesity
-
2025-521546-23-00
5
2026-04-21
Secondary progressive multiple sclerosis
-
2024-518500-47-00
4
2026-04-07
Non Small Cell Lung Cancer (NSCLC)
-
2025-522046-42-00
5
2026-03-24
Colonic disease
-
2025-522674-36-00
5
2026-03-24
Metabolic Dysfunction-Associated Steatotic Liver Disease
-
2025-522012-16-00
4
2026-03-13
Breast Cancer
-
2025-522015-42-00
10
2026-02-26
Chronic Hepatitis D Infection
-
2025-522873-12-00
5
2026-02-24
ER+, HER2- Advanced Breast Cancer
-
2024-520364-34-00
5
2026-02-23
Acute myocardial infarction
-
2025-521627-78-00
5
2026-01-28
Neoplasms, Lung
-
2024-519829-38-00
5
2026-01-09
Heart failure due to systemic left ventricular systolic dysfunction
-
2025-521128-31-00
9
2025-12-18
Locally Advanced or Metastatic Estrogen Receptor-Positive, human epide
-
2024-514500-14-00
5
2025-12-15
Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous
-
2024-513586-39-00
5
2025-12-10
Prostate Cancer
-
2024-519493-39-00
5
2025-12-09
High-risk Non-muscle-invasive Bladder
Cancer with Susceptible FGFR Alt
-
2025-521281-97-00
5
2025-12-02
Non-Small Cell Lung Cancer (NSCLC)
-
2024-517614-14-00
4
2025-11-28
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
-
2025-521920-31-00
4
2025-11-21
Graves’ Disease
-
2024-511028-15-00
4
2025-11-20
Progressive Multiple Sclerosis
-
2025-520658-12-00
4
2025-11-20
Idiopathic Pulmonary Fibrosis (IPF)
-
2024-515979-35-00
5
2025-11-13
Generalized Myasthenia Gravis
-
2024-520190-12-00
5
2025-11-10
Breast Cancer: triple negative breast cancer (TNBC) and hormone recept